Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
| Autor: | Verdun, E, Giuliani, F, Salvi, F, Stecchi, S, Reggio, A, Reggio, E, Montanari, E, Negri, G, Ludovico, L, Ghezzi, A, Zaffaroni, M, Isoardo, G, Mancardi, GIOVANNI LUIGI, Inglese, MARIA MATILDE, Carolei, A, Totaro, R, Milanese, C, La Mantia, L, Caputo, D, Mini, M, Mendozzi, L, Cotrufo, R, Oggero, A, Lus, G, Cosi, V, Romani, A, Gallai, V, Sarchielli, P, Nocentini, U, Rizzato, B, Tonali, P. A, Massaro, A. R, Rosati, G, Ferrero, B, Sotgiu, S, Annunziata, P, Barbero, P, Pipieri, A, Ricci, A, Clerico, M, Bosio, A, Cucci, M. A, Aimo, G, Giorda, L, Bortolon, F, Stenta, G, Sormani, MARIA PIA, Ecari, U, Ciampini, M, Beckmann, K, Durelli, L, Trojano, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Multiple Sclerosis Adolescent Adjuvants Immunologic Age of Onset Autoantibodies Autoimmune Diseases Female Follow-Up Studies Humans Interferon-beta Liver Diseases Longitudinal Studies Middle Aged Prospective Studies Recombinant Proteins Reference Values Immunology Virology Cell Biology medicine.disease_cause Autoimmunity Immunologic medicine Adjuvants business.industry Multiple sclerosis Thyroid Interferon beta-1b Autoantibody Interferon beta-1a medicine.disease medicine.anatomical_structure Settore MED/26 - Neurologia Liver function Thyroid function business medicine.drug |
| Popis: | Autoimmune side effects, namely autoantibody (autoAb) occurrence and thyroid function alteration, have been described during interferon-beta (IFN-beta) treatment for multiple sclerosis (MS). AutoAb occurrence and autoimmune thyroid diseases are also frequently detected in MS patients free of any treatment. The aim of this study was to evaluate the relationship between IFN-beta 1b treatment, autoAb occurrence, and autoimmune diseases in MS. Thyroid and liver function and serum autoAb (antithyroid, antinuclear, anti-liver, anti-kidney microsomes, anti-smooth muscle and parietal cell antigens) occurrence were evaluated in 156 relapsing-remitting MS (RRMS) patients before and every 3 months after starting IFN-beta 1b treatment (8 MIU subcutaneously [s.c.] on alternate days). The probability of having liver or thyroid function alteration or autoAb occurrence was analyzed longitudinally with the generalized estimating equations (GEE) approach. At baseline, 16.1% of patients had autoAb. During treatment, autoAb occurred de novo in 7.2% of patients. GEE analysis showed that the probability of having autoAb at any time during IFN-beta 1b treatment did not change significantly compared with baseline. AutoAb occurring de novo rarely persisted during treatment and significantly less than those already present at baseline. Positivity for autoAb at baseline or during treatment was not correlated with the development of thyroid or liver function alteration during IFN-beta 1b treatment. Our study indicates that IFN-beta treatment is a safe treatment for MS patients, free of risk of autoimmunity and of associated liver or thyroid function alteration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|